Filter by: patients
What is Pepcid AC?

PEPCID® Maximum Strength AC® is an over the counter brand of famotidine, a drug used to prevent and treat heartburn due to excess stomach acid.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Heartburn 11 2 Efficacy_major Efficacy_moderate
Other 4 0
Acid reflux 3 1 Efficacy_moderate
Support digestive health 2 0
Nausea 1 0
Pain 1 1 Efficacy_slight

See all 22 patients currently taking Pepcid AC

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
0
Mild
0
None
3

Reported Dosages

  10mg as needed 20mg as needed mg as needed 1 tab(s) daily 10 mg daily 20 mg daily 60 mg daily
  7 Number of Patients: 7 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 4 Number of Patients: 4 7 Number of Patients: 7 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Pepcid AC (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 2   Course of treatment ended: 40%
Did not seem to work 1   Did not seem to work: 20%
Expense 1   Expense: 20%
Other 1   Other: 20%

See all 5 patients who’ve stopped taking Pepcid AC

Currently Taking Pepcid AC

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Pepcid AC

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Pepcid AC

Always
3 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Pepcid AC

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
3 100%

Cost

Paid out of pocket

Cost of Pepcid AC

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 100%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 25, 2012.